Response to Comments: MolDX: Pharmacogenomics Testing

This record is a Response to Comments for the MolDX: Pharmacogenomics Testing Local Coverage Determination (DL38337 / L38337). It records the comment period (2019-10-22 to 2019-12-06), notice period start (2020-07-02), and LCD effective date (2020-08-17), but does not itself contain specific clinical coverage criteria, limitations, documentation requirements for claims, or frequency limits — consult LCD L38337 for those details.

"This document is the Response to Comments for the MolDX: Pharmacogenomics Testing Local Coverage Determination DL38337 (L38337)."

Sign up to see full coverage criteria, indications, and limitations.